E
Edico Genome
Biotech & Life Sciences · San Diego, United States · Founded 2013
Edico Genome is the developer of DRAGEN, the world's first Bio-IT processor for analyzing Next Generation Sequencing data. MoreLess
Edico Genome operates in the genomic testing and sequencing industry, focusing on providing advanced solutions for oncology. The company serves healthcare providers, research institutions, and pharmaceutical companies by offering comprehensive genomic profiling from both blood and tissue samples. Edico Genome's business model revolves around selling high-precision sequencing instruments, reagents, and software tools that enable accurate measurement and analysis of genetic data. Revenue is generated through the sale of these products, as well as through partnerships and collaborations that expand patient access to genomic testing. The company aims to transform cancer treatment by offering tools that predict cancer risk, identify targets for breast cancer, and facilitate liquid biopsies. Edico Genome's market includes the broader healthcare and life sciences sectors, with a particular emphasis on oncology research and personalized medicine.
Keywords: genomic testing, oncology, sequencing technology, cancer risk prediction, personalized treatment, healthcare providers, research institutions, pharmaceutical companies, liquid biopsies, genomic profiling.
Valuation & funding
Edico Genome funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | May 2018 | $0 | — | Illumina | — |
| SERIES B✓Equity / VC | May 2017 | $22M | $88M | Qualcomm Ventures · Dell Technologies Capital · Axon Ventures | — |
| SERIES A✓Equity / VC | Jul 2014 | $10M | $40M | Axon Ventures · Qualcomm Ventures | — |
| SERIES AEquity / VC | Mar 2014 | $0 | — | Moore Venture Partners | — |
| Other✓Other financing | Apr 2013 | — | — | EvoNexus | — |
Growth signals
Edico Genome website traffic
Latest recorded traffic for Edico Genome is 190 monthly website visits, up 111.1% over the last three months.
Comparisons
Edico Genome compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Edico Genome's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Edico Genome has talent and traffic
In the news
Latest news about Edico Genome
Recent press, funding announcements, and product moves mentioning Edico Genome — open to read from the original sources.
Market sentiment
What the market is saying about Edico Genome
An AI-synthesized read of the highest-engagement posts about Edico Genome on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Edico Genome’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.